Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A.

British journal of haematology - 1 Mar 2017

Batty Paul, Austin Steve K, Khair Kate, Millar Carolyn M, Palmer Ben, Rangarajan Savita, Stümpel Jan-Phillip, Thanigaikumar Murugaiyan, Yee Thynn T, Hart Daniel P

Abstract excerpt

Inhibitor formation in non-severe haemophilia A is a life-long risk and associated with morbidity and mortality. There is a paucity of data to understand real-world inhibitor screening practice. We evaluated the treatment burden, haemostatic strategies, F8 genotyping and inhibitor screening practices in non-severe haemophilia A in seven London haemophilia centres. In the 2-year study period, 44% (377/853)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIII

Share to Hemophilia A

Share to Hemostatics

Share to Infant

Share to Mass Screening

Share to Risk Assessment

Source

Identifiers

PMID: 28198996
DOI: 10.1111/bjh.14543

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A.PMID 28198996Read ↗

Mutational landscape, inhibitor development, and health-care burden in non-severe haemophilia A: A single-centre Australian experience.Semantic proximity Read ↗

Inhibitor Risk Stratification and Individualized Treatment in Patients With Nonsevere Hemophilia A: A Single-Institution Practice Audit.Semantic proximity Read ↗

The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors.Semantic proximity Read ↗

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.Semantic proximity Read ↗

HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdatasetSemantic proximity Read ↗

Survey of laboratory tests used in the diagnosis and evaluation of haemophilia A.Semantic proximity Read ↗

A large-scale computational study of inhibitor risk in non-severe haemophilia A.Semantic proximity Read ↗

Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet studySemantic proximity Read ↗

Inhibitor epidemiology and genetic-related risk factors in people with haemophilia from Côte d'Ivoire.Semantic proximity Read ↗

Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A.Semantic proximity Read ↗

Treatment related factors and inhibitor development in children with severe haemophilia A.Semantic proximity Read ↗

Acquired hemophilia A: Updated review of evidence and treatment guidance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.